Value-based care necessitates big changes for pharma marketers, says digital pharma agency

Photo courtesy of www.dialysistechniciansalary.org.

Much has been discussed, and some dismissed, when it comes to value-based care in the pharma industry. However, no one can deny that the shift to outcomes-based healthcare is a sea change that will affect big pharma significantly.

Still, exactly what does value-based care mean for pharma companies? What strategic and organizational changes will drug marketers need to make?

Intouch Solutions believes the change will require major shifts in pharma drug strategy, execution and measurement. And part of that will include a focus on value that goes beyond the product itself, three of its analysts recently wrote a point-of-view commentary.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

“The goals of brand value have to be totally different. It’s not just about selling the brand anymore, but selling the brand’s value,” Gabriel Cangiano, Intouch director, HCP and payer strategies and one of the post’s authors, told FiercePharmaMarketing. “ … We have to provide health communications that are about what people are getting from pharma that goes beyond the pill.”

Intouch is advising strategic shifts in thinking. Instead of trying to just increase drug sales or drive web traffic to a branded website, pharma now should be working on creating brand support programs around adherence and compliance and also figuring out how to prove those efforts are producing better outcomes. They should be thinking about communicating their value story to doctors and patients, instead of continuing the traditional route of simply listing benefits and risks, the company believes.

Take building a website. Traditionally, the build would focus on things like clinical data, indication information and safety and dosage facts. But in a value-based care environment, the branded site needs to build a story of value and highlight things like co-pay offsets, support programs and patient content, Cangiano said.

The good news is that some pharma companies already have experience with this more patient-centric digital marketing. Pharma tends to have closer relationships with rare diseases and chronic condition patients via online care communities and more direct communications. For example, Janssen's Prezcobix website encourages HIV patients to share their stories and lists "helpful resources" including help for medication payment prominently on its home page.

And while implementing these changes will take time and effort, brands will get a chance to "create a powerful new outcome story, to show how their service can drive results backed by data," the Intouch authors wrote in the post. "That’s a story payers and providers, under the new value-based care barometer, will care about.”

- see the Intouch blog post

Related Articles:
Express Scripts rolls out value-based pricing for cancer meds
Surprise proposal: Medicare wants to jump on the value-based pricing bandwagon
Novartis defies naysayers with newfangled pay-for-performance deals on Entresto
Who's on board with Twitter's 10,000-character limit? Pharma brand managers

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.